MONROVIA, Liberia – United States-based pharmaceutical company Mapp Biopharmaceutical has begun testing the Ebola virus treatment ZMapp in Liberia.

Dr. Jerry Brown, the head of the ELWA 2 Ebola Treatment Unit, confirmed that the ZMapp trial would be administered to about 1,000 Ebola patients in Liberia. He clarified that the trials would be continued in neighboring countries still dealing with the Ebola outbreak if there were no remaining patients in Liberia. Brown made these statements at a Ministry of Information press briefing on Feb. 26.